Brief: Compass Therapeutics Announces Presentation On CTX-8371, A Bispecific Antibody Targeting Pd-1 And Pd-L1, At The 2022 AACR Annual Meeting In New Orleans
30/03/2022 13:52
March 30 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES PRESENTATION ON CTX-8371, A
BISPECIFIC ANTIBODY TARGETING PD-1 AND PD-L1, AT THE 2022 AACR
ANNUAL MEETING IN NEW ORLEANS
Source text for Eikon: ID:nGNX2Vhy36
Further company coverage: CMPX.O
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback